Publication | Closed Access
Randomized prospective trial comparing 5-fluorouracil (NSC-19893) to 5-fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer.
28
Citations
0
References
1976
Year
Advanced Gastrointestinal CancerOncologyImproved Response RateGastrointestinal OncologyMedicineSouthwest Oncology GroupDrug CombinationGastroenterologyPathologyPharmacotherapyAnti-cancer AgentCancer TreatmentProspective TrialPharmacologyRadiation OncologyCancer ResearchMolecular OncologyDrug Discovery
The Southwest Oncology Group has confirmed the superiority of 5-fluorouracil (5-FU) and methyl-CCNU versus 5-FU weekly as treatment for patients with advanced gastrointestinal cancers. The drug combination produced a PR rate of 29.3% compared to the single-drug arm rate of 10.6%; however, the two-drug arm produced much more toxicity. Despite the improved response rate no improvement in survival was observed.